Posted 10 April 2017
By Charu Manaktala, MD, MBBS, Raymond A. Huml, MS, DVM, RAC, Nigel Rulewski, MD
This article examines key strategies being adopted by the innovator companies and discusses the impact these strategies are likely to have on the future market for biosimilars.
Share this article:
Categories: Biologics and biotechnology, Government affairs, Regulatory strategy, Submission and registration, Features, US, Europe, FDA, EMA
Tags: Biosimilars, Intellectual Property, Litigation, Patent Extension